Lv1
100 积分 2025-07-03 加入
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
1个月前
已完结
Screening Non-neutralizing Anti-idiotype Antibodies Against a Drug Candidate for Total Pharmacokinetic and Target Engagement Assay
6个月前
已完结
Bispecific antibody drug conjugates: Making 1+1>2
8个月前
已完结
Development of an ELISA with acidification treatment for an antibody conjugate incorporating Exatecans
8个月前
已完结
皖公网安备34019202002308
